Loading...
•
Mar 31, 2022
Sight Sciences Q1 2022 Earnings Report
Reported financial results, demonstrating revenue growth and expanded gross margin.
Key Takeaways
Sight Sciences reported a strong first quarter with a 72% increase in revenue compared to the prior year period, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company also expanded its gross margin to 80%.
Total revenue increased by 72% to $14.9 million compared to the prior year period.
The number of facilities ordering the OMNI® Surgical System increased from 760 to 811.
The installed base of TearCare® facilities grew from 562 to 635.
Gross margin expanded to 80% compared to 73% in the prior year period.
Sight Sciences
Sight Sciences
Sight Sciences Revenue by Segment
Revenue by Segment
Surgical Glaucoma Revenue
CapyFin.comDry Eye Revenue
CapyFin.com Forward Guidance
Sight Sciences projects full year 2022 revenue to range from $67 million to $75 million, representing growth of approximately 37% to 53% compared to 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income